Letting the Target Determine your Compound Acquisition Strategy By Dr John Harris With compound libraries likely to remain the cornerstone of hit and lead discovery for the foreseeable future, this paper seeks to summarise current and future approaches to optimal library design and compound acquisition, using examples and experimental evidence… Read More
High Throughput Screening, High Content Screening, Primary and Stem Cells By Dr Richard M. Eglen Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies. Furthermore, a wide… Read More
Livening up HCS Imaging By Dr John Comley With the aid of recent end-user feedback, this article investigates interest in and use of live cell and kinetic HCS imaging; most wanted application areas: advantages of live cell HCS imaging; live cell HCS assays of greatest interest; what's limiting live cell… Read More
High Content Screening - The next challenge: effective data mining and exploration By Dr Kurt Zingler and Dr Stephan Heyse The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount. Over the… Read More
High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More
Next Generation Immunoassay Systems and the Revival of Protein Biomarkers By Dr John Todd and Dr Sara J. Agee Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology. Advances in immunoassay technology,… Read More
Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium… Read More
Growing Interest in Outsourcing Ion Channel Services By Dr John Comley Summer 2008 Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings. In the highly competitive area of cardiac safety hERG testing… Read More
Progress in the Implementation of Label-Free Detection - Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec's recent Cell-Based Label-Free Detection Trends report. Uniquely all of these label-free offerings are plate-based and… Read More
Emerging Real-time PCR Applications Dr Mikael Kubista Since its introduction on the commercial market little more than 10 years ago, real-time PCR has become the main technical platform for nucleic acid detection in research and development, as well as in routine diagnostics. In 2007 the real-time PCR market revenue in… Read More
Data Overflow Progress in Automating and Streamlining Data By Peer Staehler The genomic world moves faster and faster. The pool of data has exploded exponentially in the past few years due to the growing knowledge about the relevance of genomic findings for medicine and the environment. Like all other developing… Read More
Transcending Proteasome Inhibition for the Treatment of Cancer By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS). Specific pharmacological inhibition of… Read More
The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More
Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More
Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More
Trends in the microRNA Marketplace By Kathy Gray and Dr Enal Razvi In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market analyses are presented in detail in a recently published MicroRNA 2008 market report. Read More